Your browser is no longer supported. Please, upgrade your browser.
JNJ Johnson & Johnson daily Stock Chart
Johnson & Johnson
IndexDJIA S&P500 P/E22.92 EPS (ttm)5.95 Insider Own0.02% Shs Outstand2.71B Perf Week1.69%
Market Cap369.02B Forward P/E17.80 EPS next Y7.66 Insider Trans-20.36% Shs Float2.69B Perf Month6.91%
Income16.51B PEG3.55 EPS next Q1.80 Inst Own67.90% Short Float0.59% Perf Quarter8.38%
Sales72.17B P/S5.11 EPS this Y8.30% Inst Trans0.05% Short Ratio2.79 Perf Half Y18.10%
Book/sh25.99 P/B5.25 EPS next Y7.90% ROA11.70% Target Price131.83 Perf Year17.91%
Cash/sh14.54 P/C9.38 EPS next 5Y6.45% ROE23.10% 52W Range109.32 - 137.00 Perf YTD18.34%
Dividend3.36 P/FCF43.08 EPS past 5Y11.20% ROI17.00% 52W High-0.48% Beta0.78
Dividend %2.46% Quick Ratio2.20 Sales past 5Y2.00% Gross Margin69.90% 52W Low24.72% ATR1.22
Employees126400 Current Ratio2.50 Sales Q/Q1.60% Oper. Margin27.80% RSI (14)86.77 Volatility0.82% 0.89%
OptionableYes Debt/Eq0.46 EPS Q/Q1.00% Profit Margin22.90% Rel Volume0.96 Prev Close136.43
ShortableYes LT Debt/Eq0.38 EarningsJul 18 BMO Payout52.80% Avg Volume5.72M Price136.34
Recom2.50 SMA203.49% SMA507.04% SMA20013.31% Volume5,506,015 Change-0.07%
May-18-17Reiterated Stifel Hold $124 → $128
May-15-17Upgrade JP Morgan Neutral → Overweight
Jan-26-17Downgrade Wells Fargo Outperform → Market Perform
Jan-25-17Reiterated RBC Capital Mkts Outperform $133 → $128
Oct-19-16Reiterated UBS Buy $137 → $144
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jun-26-17 01:53PM  This classic Dow stock has come too far, too fast: Technician CNBC
08:47AM  J&J CEO Gorsky on M&A, Health Care, Tax Reform Bloomberg Video
08:32AM  J&J CEO Gorsky Says Health Care Labor Market Is Tight Bloomberg Video
08:26AM  J&J CEO Gorsky Says Health Care Needs 10-20 Years of Work Bloomberg Video
08:20AM  J&J CEO Gorsky Says U.S. Tax Reform Is Essential Bloomberg Video
Jun-25-17 11:12AM  3 Dividend Stocks for Smart Investors Motley Fool
11:01AM  3 Reasons to Buy Celgene Stock and Never Sell Motley Fool
Jun-24-17 08:03AM  Portola Pharmaceuticals' FDA Nod Could Spark M&A Interest Motley Fool
07:45AM  The 3 Best Dividend Stocks for Beginning Investors Motley Fool
Jun-23-17 01:33PM  Trumps adds NY Jets owner to diplomatic roster Yahoo Finance Video
12:11PM  A New ETF For Low Vol ETFs Benzinga
09:19AM  Dow 30 Stock Roundup: Boeing Bags Big Orders at Paris Air Show; Wal-Mart to Buy Bonobos Zacks
09:07AM  How Alphabets YouTubes Ad Boycotters Fared Market Realist
09:00AM  Healthcare ETF (IYH) Hits New 52-Week High Zacks
04:08AM  Five must-knows if you want to become a chief marketing officer, by Diageo, Johnson & Johnson and HP CNBC
02:41AM  Five must-knows if you want to become a chief marketing officer, by Diageo, Johnson & Johnson and HP CNBC
Jun-22-17 04:12PM  Markets Right Now: US stock indexes drift to a mixed close Associated Press
04:07PM  UnitedHealth, HCA, Merck Rally As Senate TrumpCare Bill Pares Near-Term Cuts Investor's Business Daily
02:03PM  Stock market climbs as health-care shares extend rally MarketWatch
11:38AM  Does Valeant Pharmaceuticals Intl Inc (VRX) Stock Have a Bull Case? InvestorPlace
10:36AM  Here's Why Geron (GERN) is a Good Stock to Invest in Now Zacks
09:42AM  3 Perfect Stocks for Retirees in Their 70s to Consider Buying Motley Fool
08:40AM  Johnson & Johnson seeks to have Missouri talc suits dismissed American City Business Journals
08:04AM  Johnson & Johnson Releases 2016 Health for Humanity Report PR Newswire
12:36AM  [$$] Missouri Files Its Own Suit Against Opioid-Painkiller Producers The Wall Street Journal
Jun-21-17 07:01PM  Cramer: This Is No Country for Old Value
06:12PM  Cramer finds where the real growth is in a split market CNBC
05:48PM  Finding real growth in a split market CNBC Videos
04:18PM  [$$] Big Medtech Buys May Be Busts
01:50PM  Dems Roast Trump for Leaving Medicare Out of Drug Price Order
01:46PM  [$$] J&J Seeking Dismissal of Talc Lawsuits in Missouri The Wall Street Journal
01:24PM  [$$] Missouri Files Its Own Suit Against Opioid-Painkiller Producers The Wall Street Journal
10:00AM  S&P 500 Buybacks Fall 17.5% Year-over-Year to $133.1 Billion for Q1 2017 PR Newswire
09:30AM featured highlights: Johnson & Johnson, NantKwest, Delek US Holdings, Abbot Labs and Winnebago Zacks
09:08AM  Analyzing Bristol-Myers Squibbs Valuation on June 20 Market Realist
09:03AM  Major Talc Case Against J&J Declared a Mistrial Following SCOTUS Ruling
07:49AM  Early movers: TGT, FDX, JNJ, PYPL, TSLA, CVX, ADBE & more CNBC
07:00AM  U.S. Supreme Court ruling threatens massive talc litigation against J&J Reuters
Jun-20-17 09:58PM  U.S. Supreme Court ruling threatens massive talc litigation against J&J Reuters
09:45PM  U.S. Supreme Court ruling threatens massive talc litigation against J&J Reuters
07:40PM  Supreme Court ruling threatens massive talc litigation against J&J Reuters
06:05PM  Why Pomalyst Could See Significant Revenue Growth in 2017 Market Realist
05:46PM  High Court ruling may hurt claims of talc link to cancer Associated Press
05:43PM  A Short-Term Dip Is a Great Time to Consider Buying These Long-Term Stocks Motley Fool
05:37PM  How to Uncover Institutional Buying Zacks
05:35PM  Five classic Dow stocks are surging CNBC Videos
04:20PM  Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results PR Newswire
04:16PM  High Court ruling may hurt claims of talc link to cancer Associated Press
03:04PM  ETFs with exposure to Johnson & Johnson : June 20, 2017 Capital Cube
02:45PM  How Did Celgene Perform in 1Q17? Market Realist
11:28AM  J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study Zacks
10:40AM  Exxon, BP support Republican elders' climate proposal Reuters
10:25AM  Mistrial declared in talc suit following Supreme Court ruling American City Business Journals
09:00AM  2 Big Dividend Plays Near Buy Point; Which One Owns Microsoft? Investor's Business Daily
08:04AM  Should Investors Steer Clear of Opioid Drug Stocks? Motley Fool
08:00AM  Douglas Wallace, Ph.D., Wins 2017 Dr. Paul Janssen Award for Biomedical Research PR Newswire
Jun-19-17 09:40PM  Procter & Gamble Could Be Nearing a Bruising Battle With This Legendary Activist Investor
06:10PM  U.S. Supreme Court again limits where companies can be sued Reuters
05:25PM  Supreme Court ruling results in talc lawsuit mistrial Associated Press
12:45PM  5 Dow Components Set New Highs On Friday, Here's How To Trade Them Now Forbes
12:23PM  Just 10 stocks are having an incredible impact on the market this year CNBC
12:03PM  Johnson & Johnson :JNJ-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017 Capital Cube
10:28AM  AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run? Zacks
09:59AM  Company News for June 19, 2017 Zacks
08:43AM  J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use Zacks
08:20AM  5 Stocks That Pay You to Own Them Motley Fool
08:15AM  Featured Company News - J&J Completes Actelion Acquisition Accesswire
06:00AM  Health Care Stocks Are Crushing the S&P 500 Investopedia
Jun-18-17 06:42AM  5 Reasons the Boring Parts of Johnson & Johnson's Business Should Generate Excitement Motley Fool
Jun-16-17 06:02PM  Tech Stocks Report Losses for the Week
03:34PM  [$$] Actelion spin-off Idorsia up 30% on market debut Financial Times
12:02PM  3 Hiddem Gems in the Healthcare Sector Motley Fool
08:27AM  Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused Zacks
08:15AM  Featured Company News - Johnson & Johnson Announces Flu Drug Update; Pimodivir Succeeds Mid-Stage Trial Accesswire
07:29AM  Actelion spin-off Idorsia's shares rise 30 pct in market debut Reuters
03:05AM  Actelion spin-off Idorsia makes market debut at 10 Sfr per share Reuters
01:00AM  Johnson & Johnson Announces Completion of Acquisition of Actelion PR Newswire
Jun-15-17 04:10PM  Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J
03:20PM  Could This Small Biotech Pique Interest Of Gilead And Others? Investor's Business Daily
11:19AM  Opioid Marketing Under Bipartisan Investigation
10:47AM  Johnson & Johnson's Type 2 Diabetes Drug Is Stellar in Cardiovascular Trials, but Comes With a Catch Motley Fool
07:36AM  How Is AbbVie Expected to Perform in 2017? Market Realist
07:00AM  3 Recent Buys From Top Large-Cap Managers Morningstar
06:04AM  8 Brand-Name Companies Paying Out at Least $8 Billion in Dividends a Year Motley Fool
12:20AM  [$$] J&J Plans to Add Drug Discovery and Early Research to Actelion Unit The Wall Street Journal
Jun-14-17 08:58PM  States Launch Bipartisan Probe of Opioid Marketing and Addiction The Wall Street Journal
07:01PM  Google bets on European biotech drugs, backs new fund Reuters
04:43PM  Johnson & Johnson: The Bear Case From a Bull Motley Fool
03:48PM  Seven iQ100 members hit all-time highs CNBC Videos
03:23PM  [$$] J&J to Add Drug Discovery, Early Research to Actelion The Wall Street Journal
11:30AM  US STOCKS-Weak data weighs on bank stocks; Fed rate decision looms Reuters
11:12AM  [$$] JNJ Diabetes Data Benefit Lilly, Hurt Merck
10:14AM  Stock market struggles to extend records as investors await Feds signals MarketWatch
10:05AM  US STOCKS-Wall St flat as banks fall after weak data; Fed eyed Reuters
09:37AM  Johnson & Johnson's flu drug succeeds in mid-stage trial Reuters
09:01AM  Johnson & Johnson Sees Success with Flu Treatment Trial
08:04AM  3 Top Safe Dividend Stocks Motley Fool
07:37AM  Why Viekira Could Witness a Modest Revenue Fall in 2017 Market Realist
07:25AM  Johnson & Johnson's flu drug succeeds in mid-stage trial Reuters
07:12AM  Johnson & Johnson's flu drug succeeds in mid-stage trial Reuters
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising brand adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Duato JoaquinExec VP, WW Chair, PharmaMar 03Option Exercise59.7650,0002,987,780118,536Mar 07 04:21 PM
Duato JoaquinExec VP, WW Chair, PharmaMar 03Sale123.6250,0006,181,14068,536Mar 07 04:21 PM
Kapusta Ronald AController, CAOFeb 28Option Exercise72.5414,5431,054,94944,507Mar 02 05:50 PM
Kapusta Ronald AController, CAOFeb 28Sale122.2614,5431,777,95429,964Mar 02 05:50 PM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 28Sale122.2116,2991,991,94343,630Mar 02 05:16 PM
Stoffels PaulusExec VP, Chief Scientific OffFeb 15Sale117.2922,0002,580,274127,650Feb 16 06:53 PM
Caruso Dominic JExec VP, Finance; CFOFeb 13Option Exercise0.0026,9470150,700Feb 15 10:00 PM
Kapusta Ronald AController, CAOFeb 13Option Exercise0.002,148030,052Feb 16 06:01 AM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 13Option Exercise0.0015,532063,405Feb 16 06:01 AM
Duato JoaquinExec VP, WW Chair, PharmaFeb 13Option Exercise0.0022,298075,814Feb 16 06:01 AM
Fasolo PeterExec VP, Chief HR OfficerFeb 13Option Exercise0.0015,598068,899Feb 16 06:01 AM
Gorsky AlexChairman, CEOFeb 13Option Exercise0.0084,2990280,617Feb 16 06:01 AM
PETERSON SANDRA EExec VP, Group WW ChairmanFeb 13Option Exercise0.0027,667069,436Feb 16 06:01 AM
Stoffels PaulusExec VP, Chief Scientific OffFeb 13Option Exercise0.0026,4470156,125Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 13Option Exercise0.0014,6000114,866Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 01Option Exercise65.6227,7351,819,971119,190Feb 03 12:05 PM
Ullmann Michael HExec VP, General CounselFeb 01Sale112.8821,7352,453,44297,455Feb 03 12:05 PM
PRINCE CHARLESDirectorOct 21Buy114.1187599,84626,520Oct 25 01:52 PM
JOHNSON & JOHNSON10% OwnerAug 16Buy12.00583,3336,999,9962,449,183Aug 18 05:11 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Option Exercise65.6241,1462,700,001157,819Jul 28 04:34 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Sale125.0141,1465,143,810116,673Jul 28 04:34 PM
Kapusta Ronald AController, CAOJul 22Sale125.012,935366,89625,725Jul 25 03:18 PM
Kapusta Ronald AController, CAOJul 21Option Exercise58.332,935171,19928,660Jul 25 03:18 PM